Genome edited iPSCs (KO) PARK2-/- *MTA
Catalog # :
1 vial (1 x 10^6)
* Price listed above is for academic institutions for research purposes only
MTA is required
Applied StemCell's Genome Edited series of iPSC lines are ideal as in vitro models for neurodegenerative diseases such as Parkinson’s Disease, Alzheimer’s Disease, ALS, Autism and more. The ASE-9403 iPSC line is engineered with a bi-allelic (homozygous) knockout for LRRK2 gene (PARK2-/-) that has been implicated in Parkinson’s disease. The parental iPSC is ASE-9109 which is an integration-free, normal karyotype iPSC derived from male, CD34+ cord blood cells. The LRRK2 knockout line can be further differentiated into an isogenic panel of neurons and glia for disease modeling and drug/ toxicity screening applications.